gemfibrozil has been researched along with Disease Exacerbation in 17 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Disease progression is associated with variation in AAT, and low AAT levels promote atherogenesis." | 2.71 | Progression of atherosclerosis is associated with variation in the alpha1-antitrypsin gene. ( Flavell, DM; Frick, MH; Humphries, SE; Jackson, R; Kesäniemi, YA; Martin, S; Nagl, S; Nieminen, MS; Pasternack, A; Steiner, G; Syvänne, M; Talmud, PJ; Taskinen, MR; Whitehouse, DB, 2003) |
| "Gemfibrozil therapy was associated with a median 18% increase in tHcy levels (P < 0." | 2.71 | Serum homocysteine concentrations, gemfibrozil treatment, and progression of coronary atherosclerosis. ( Frick, MH; Humphries, SE; Kesäniemi, YA; Nieminen, MS; Pasternack, A; Syvänne, M; Taskinen, MR; Turpeinen, U; Whittall, RA, 2004) |
| "The progression of coronary atherosclerosis was estimated by quantitative, computer-assisted analysis of coronary artery stenoses from the baseline angiograms and from repeated angiograms performed an average of 32 months later." | 2.69 | Heart rate variability and progression of coronary atherosclerosis. ( Airaksinen, KE; Frick, MH; Huikuri, HV; Ikäheimo, MJ; Jokinen, V; Kauma, H; Kesäniemi, AY; Koistinen, JM; Majahalme, S; Niemelä, KO; Nieminen, MS; Syvänne, M, 1999) |
| "Fifteen normotensive NIDDM patients with hypertriglyceridaemia (> 2." | 2.68 | Can reduction in hypertriglyceridaemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus? ( Silberbusch, J; Slaats, EH; Smulders, YM; Stehouwer, CD; van Eeden, AE; Weijers, RN, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (35.29) | 18.2507 |
| 2000's | 9 (52.94) | 29.6817 |
| 2010's | 2 (11.76) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Qaseem, A | 1 |
| Hopkins, RH | 1 |
| Sweet, DE | 1 |
| Starkey, M | 1 |
| Shekelle, P | 1 |
| Talmud, PJ | 4 |
| Martin, S | 2 |
| Steiner, G | 1 |
| Flavell, DM | 2 |
| Whitehouse, DB | 1 |
| Nagl, S | 1 |
| Jackson, R | 1 |
| Taskinen, MR | 7 |
| Frick, MH | 8 |
| Nieminen, MS | 7 |
| Kesäniemi, YA | 7 |
| Pasternack, A | 7 |
| Humphries, SE | 5 |
| Syvänne, M | 8 |
| Garber, AJ | 1 |
| Viles-Gonzalez, JF | 1 |
| Fuster, V | 1 |
| Corti, R | 1 |
| Badimon, JJ | 1 |
| Whittall, RA | 1 |
| Turpeinen, U | 1 |
| Whitney, EJ | 1 |
| Krasuski, RA | 1 |
| Personius, BE | 1 |
| Michalek, JE | 1 |
| Maranian, AM | 1 |
| Kolasa, MW | 1 |
| Monick, E | 1 |
| Brown, BG | 1 |
| Gotto, AM | 1 |
| Calkin, AC | 1 |
| Giunti, S | 1 |
| Jandeleit-Dahm, KA | 1 |
| Allen, TJ | 1 |
| Cooper, ME | 1 |
| Thomas, MC | 1 |
| Kauma, H | 3 |
| Majahalme, S | 3 |
| Virtanen, V | 2 |
| Smulders, YM | 1 |
| van Eeden, AE | 1 |
| Stehouwer, CD | 1 |
| Weijers, RN | 1 |
| Slaats, EH | 1 |
| Silberbusch, J | 1 |
| Hoogerbrugge, N | 1 |
| Kerkhofs, LG | 1 |
| Jansen, H | 1 |
| Luong, LA | 1 |
| Ehnholm, C | 1 |
| Huikuri, HV | 1 |
| Jokinen, V | 1 |
| Airaksinen, KE | 1 |
| Ikäheimo, MJ | 1 |
| Koistinen, JM | 1 |
| Kesäniemi, AY | 1 |
| Niemelä, KO | 1 |
| Jamshidi, Y | 1 |
| Hawe, E | 1 |
| Pineda Torra, I | 1 |
| Staels, B | 1 |
| Miller, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Double-blind, Placebo-controlled Trial of Niaspan® in Patients With Overt Diabetic Nephropathy and Moderate Renal Impairment[NCT00108485] | Phase 3 | 9 participants (Actual) | Interventional | 2005-04-30 | Terminated (stopped due to Unable to recruit sufficient study subjects) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00108485)
Timeframe: Baseline, 1 year
| Intervention | mg/dL (Number) |
|---|---|
| Extended Release Niacin | 42 |
| Placebo | 63 |
2 reviews available for gemfibrozil and Disease Exacerbation
| Article | Year |
|---|---|
Cardiovascular complications of diabetes: prevention and management.
Topics: Blood Pressure; Diabetic Angiopathies; Disease Progression; Gemfibrozil; Humans; Hydroxymethylglutar | 2003 |
Emerging importance of HDL cholesterol in developing high-risk coronary plaques in acute coronary syndromes.
Topics: Animals; Cholesterol, HDL; Coronary Artery Disease; Coronary Disease; Disease Progression; Endotheli | 2003 |
9 trials available for gemfibrozil and Disease Exacerbation
| Article | Year |
|---|---|
Progression of atherosclerosis is associated with variation in the alpha1-antitrypsin gene.
Topics: 3' Untranslated Regions; Aged; Alleles; alpha 1-Antitrypsin; alpha 1-Antitrypsin Deficiency; Amino A | 2003 |
Serum homocysteine concentrations, gemfibrozil treatment, and progression of coronary atherosclerosis.
Topics: Cholesterol, HDL; Coronary Angiography; Coronary Artery Disease; Disease Progression; Double-Blind M | 2004 |
A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events.
Topics: Aged; Cholesterol, HDL; Cholestyramine Resin; Coronary Angiography; Coronary Disease; Disease Progre | 2005 |
Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group.
Topics: Aged; Analysis of Variance; Arteriosclerosis; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coron | 1997 |
Can reduction in hypertriglyceridaemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus?
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dise | 1997 |
Gemfibrozil decreases autoantibodies against oxidized low-density lipoprotein in men with combined hyperlipidaemia.
Topics: Adult; Aged; Autoantibodies; Disease Progression; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemi | 1998 |
The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study. Lopid Coronary Angiography Trial.
Topics: Aged; Coronary Angiography; Coronary Disease; Disease Progression; Double-Blind Method; Gemfibrozil; | 1998 |
Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol.
Topics: Apolipoproteins; Cholesterol; Cholesterol, HDL; Coronary Angiography; Coronary Artery Bypass; Corona | 1998 |
Heart rate variability and progression of coronary atherosclerosis.
Topics: Analysis of Variance; Coronary Angiography; Coronary Artery Disease; Coronary Disease; Disease Progr | 1999 |
6 other studies available for gemfibrozil and Disease Exacerbation
| Article | Year |
|---|---|
Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: A clinical practice guideline from the American College of Physicians.
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2013 |
Summaries for patients. Screening, monitoring, and treatment of early stage chronic kidney disease: recommendations from the American College of Physicians.
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2013 |
APOA5 gene variants, lipoprotein particle distribution, and progression of coronary heart disease: results from the LOCAT study.
Topics: Aged; Apolipoprotein A-V; Apolipoproteins; Apolipoproteins A; Arteriosclerosis; Coronary Disease; Di | 2004 |
Summaries for patients. Targeting cholesterol treatment toward increasing high-density lipoprotein levels.
Topics: Aged; Cholesterol, HDL; Cholestyramine Resin; Coronary Angiography; Coronary Disease; Disease Progre | 2005 |
PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse.
Topics: Animals; Apolipoproteins E; Collagen Type IV; Creatinine; Diabetic Nephropathies; Disease Models, An | 2006 |
Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease.
Topics: Aged; Alleles; Amino Acid Substitution; Arteriosclerosis; Clinical Trials as Topic; Cohort Studies; | 2002 |